Kruck Stephan, Gakis Georgios, Stenzl Arnulf
Department of Urology, Eberhard-Karls University, Hoppe Seyler-Straße 3, 72076 TÜbingen, Germany.
Adv Urol. 2012;2012:135281. doi: 10.1155/2012/135281. Epub 2011 Aug 21.
Management of prostate cancer is recognized as one of the most important medical problems. Latest findings concerning the role of circulating (CTC) and disseminated tumor cells (DTC) have provided new insights into the biology of metastasis with important implications for the clinical management of prostate cancer patients. Most of the established methods of circulating/disseminated tumor cell enrichment use density-gradient centrifugation and immunomagnetic procedures. Reverse transcriptase polymerase chain reaction is another used detection technique. Novel methods, the CTC-chip and the epithelial immunospot assay already showed promising results. For localized and metastatic prostate cancer, significant correlations between spreading tumor cells and well-established indicators of disease activity have been demonstrated. Careful randomized prospective trials will be required to justify the routine use of CTCs/DTCs for therapy decision making.
前列腺癌的管理被认为是最重要的医学问题之一。关于循环肿瘤细胞（CTC）和播散肿瘤细胞（DTC）作用的最新研究结果为转移生物学提供了新的见解，对前列腺癌患者的临床管理具有重要意义。大多数已确立的循环/播散肿瘤细胞富集方法采用密度梯度离心和免疫磁分离程序。逆转录聚合酶链反应是另一种常用的检测技术。新型方法，即CTC芯片和上皮免疫斑点分析已经显示出有前景的结果。对于局限性和转移性前列腺癌，已证明播散肿瘤细胞与成熟的疾病活动指标之间存在显著相关性。需要进行严谨的随机前瞻性试验，以证明将CTC/DTC常规用于治疗决策的合理性。
